| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-11- | | | | | 异常期间涨跌幅偏离值累计 | | 29 | 839790 | 联迪信息 | 40522037.0 | 141355.65 | 达到56.18% | | 2024-11- | | | | | | | 29 | 834765 | 美之高 | 10725691.0 | 25623.66 | 当日收盘价涨幅达到30.00% | | 2024-11- | 830896 | 旺成科技 | 14593680.0 | 28204.85 | 当日收盘价涨幅达到30.00% | | 29 | | | | | | | 2024-11- | 873132 | 泰鹏智能 | 15811947.0 | 31825.95 | 当日收盘价涨幅达到30.00% | | 29 | | | | | | | 2024-11- | 834407 | 驰诚股份 | 4885612 | 14250.19 | 当日收盘价涨幅达到29.98% | | 2 ...

证券代码：833429 证券简称：康比特 公告编号：2024-070 北京康比特体育科技股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 11 月 15 日 2.会议召开地点：北京市昌平区何营路九号院康比特健康产业园 2 号楼 2 层 会议室 3.会议召开方式：现场投票与网络投票相结合 4.会议召集人：董事会 5.会议主持人：董事长白厚增先生 6.召开情况合法、合规、合章程性说明： 本次会议召集、召开、议案审议程序等方面符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的规定。 （二）会议出席情况 出席和授权出席本次股东大会的股东共 17 人，持有表决权的股份总数 61,273,478 股，占公司有表决权股份总数的 49.44%。 其中通过网络投票参与本次股东大会的股东共 2 人，持有表决权的股份总数 11,471,964 股，占公司有表决权股份总数的 9.26%。 ...

关于北京康比特体育科技股份有限公司 2024 年第一次临时股东大会的法律意见书 致：北京康比特体育科技股份有限公司 北京市君致律师事务所（以下简称"本所"）接受北京康比特体育科技股份 有限公司（以下简称"公司"）的委托，指派律师出席了公司于 2024 年 11 月 15 日召开的 2024 年第一次临时股东大会（以下简称"本次股东大会"）。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完 整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗 漏，并承担相应法律责任。 在审查有关文件的过程中，公司保证，其向本所提交的文件和所做的说明是 真实的、准确的、完整的，并已提供出具本法律意见书所必需的文件材料或口头 证言，并保证其所提供的有关副本材料或复印件与正本或原件一致。 本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》《北京 证券交易所股票上市规则（试行 ...

证券代码：833429 证券简称：康比特 公告编号：2024-069 北京康比特体育科技股份有限公司 章 程 二零二四年十一月 1 | | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 股份发行 | 4 | | 第二节 股份增减和回购 | 5 | | 第三节 股份转让 | 7 | | 第四章 | 股东和股东大会 8 | | 第一节 股东 | 9 | | 第二节 | 股东大会的一般规定 12 | | 第三节 股东大会的召集 | 17 | | 第四节 股东大会的提案与通知 | 19 | | 第五节 股东大会的召开 | 20 | | 第六节 股东大会的表决和决议 | 23 | | 第五章 | 董事会 27 | | 第一节 | 董事 27 | | 第二节 | 董事会 31 | | 第三节 | 董事会秘书 36 | | 第四节 | 独立董事 38 | | 第六章 | 总经理及其他高级管理人员 42 | | 第七章 | 监事会 44 | | 第一节 | 监事 44 | | 第二节 | 监事会 45 | | 第三节 | 监事会 ...

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2] Core Views - The company has shown robust revenue growth, with a year-on-year increase of 20.13% in Q3 2024 and a cumulative revenue of 774 million yuan for the first three quarters of 2024, representing a 29.84% increase year-on-year [5] - The company is increasing its investment in the "Sports Nutrition Food Production Base Construction Project," raising the planned investment from 126 million yuan to 309 million yuan due to rapid market demand for solid and liquid products [6] - The company is expected to benefit from the high demand in the sports nutrition industry, with a strong competitive edge in product quality and channel distribution [7] Financial Performance - The company achieved a net profit of 66 million yuan in the first three quarters of 2024, a 2.06% increase year-on-year, while the non-recurring net profit rose by 27.25% to 65 million yuan [5] - The gross profit margin for Q3 2024 was 37.64%, down 3.18 percentage points year-on-year, primarily due to rising raw material costs [6] - The company forecasts revenues of 1,001 million yuan for 2024, with a year-on-year growth of 18.8%, and net profits of 98 million yuan, reflecting an 11% increase [10] Valuation and Earnings Forecast - The estimated earnings per share (EPS) for 2024, 2025, and 2026 are projected to be 0.79 yuan, 0.99 yuan, and 1.25 yuan respectively [10] - The company is assigned a price-to-earnings (P/E) ratio of 16-20 times for 2025, leading to a reasonable valuation range of 15.84 to 19.8 yuan per share [7]

证券代码：833429 证券简称：康比特 公告编号：2024-067 北京康比特体育科技股份有限公司 回购进展情况公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 回购方案基本情况 公司董事会审议通过回购股份方案前 30 个交易日（不含停牌日）交易均价为 10.00 元，拟回购价格上限不低于上述价格，不高于上述价格的 200%。为保护投资者利益， 结合公司目前的财务状况、经营状况及近期公司股价，确定本次回购价格不超过 13 元/ 股，具体回购价格由公司股东大会授权董事会在回购实施期间，综合公司二级市场股票 价格、公司财务状况和经营状况确定。 自董事会决议至回购完成期间，如公司存在权益分派等事项，将自权益分派实施之 日起，及时调整回购价格。 调整公式为：P＝（P0﹣V*Q/Q0）/（1+n） 其中：P0 为调整前的回购每股股份的价格上限；V 为每股的派息额；Q 为扣除已回 购股份数的公司股份总额；Q0 为回购前公司原股份总额；n 为每股公积金转增股本、派 送股票红利、股票拆细的比率（即每股股票经转 ...

Investment Rating - The report maintains a "Recommended" rating for the company 康比特 (833429.BJ) [4] Core Views - The company reported a revenue of 774 million yuan for the first three quarters of 2024, representing a year-on-year growth of 29.84%. The net profit attributable to shareholders was 65.56 million yuan, a slight increase of 2.06% year-on-year, while the non-deductible net profit grew by 27.25% to 64.91 million yuan [1] - The company is increasing its investment in production capacity due to rising demand for its products, planning to raise the total investment for its "Sports Nutrition Food Production Base" project from 126 million yuan to 309 million yuan, with an expected completion date in August 2026 [2] - Continuous product innovation is a focus, with new product launches expected to capture a larger market share in the growing sports nutrition sector, which is still in its early stages in China [2] - The domestic sports nutrition industry is projected to maintain a high level of prosperity, with the company positioned as a leader in the market, benefiting from both online and offline sales channels [2] Financial Forecasts - The company is expected to achieve revenues of 1.012 billion yuan, 1.202 billion yuan, and 1.422 billion yuan for the years 2024, 2025, and 2026, respectively, with corresponding net profits of 100 million yuan, 121 million yuan, and 135 million yuan [3] - The earnings per share (EPS) are projected to be 0.80 yuan, 0.97 yuan, and 1.08 yuan for the same years, with price-to-earnings (PE) ratios of 19.93, 16.42, and 14.78 [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [1][4]. Core Insights - The company achieved a revenue of 774 million yuan in Q1-Q3 2024, a year-on-year increase of 29.84%, and a net profit attributable to shareholders of 65.56 million yuan, up 2.06% from the previous year. The net profit excluding non-recurring items increased by 27.25% [2]. - The growth in revenue is primarily driven by the expansion of the sports nutrition and general nutrition product lines, supported by increased marketing efforts, which saw sales expenses rise by 48.84% to 128 million yuan [2]. - The sports industry is experiencing growth due to national policies promoting sports development, with the number of fitness enthusiasts in China expected to exceed 460 million by 2027, creating favorable conditions for the demand for sports health products [3]. - The company has been increasing its R&D investment, with an average R&D expenditure of 18.66 million yuan from 2018 to 2022, and a significant increase to over 30 million yuan in 2023, reflecting its strong R&D capabilities [3]. - The company is expected to achieve net profits of 104 million yuan, 123 million yuan, and 144 million yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.83 yuan, 0.99 yuan, and 1.16 yuan per share [4]. Financial Summary - Total revenue is projected to grow from 843.22 million yuan in 2023 to 1,404.06 million yuan in 2026, with a compound annual growth rate (CAGR) of 14.86% [1][4]. - The company's net profit is expected to increase from 88.10 million yuan in 2023 to 143.85 million yuan in 2026, with a CAGR of 17.24% [1][4]. - The current P/E ratios are projected to decrease from 22.61 in 2023 to 13.85 in 2026, indicating an attractive valuation as earnings grow [1][4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [1][4]. Core Insights - The company achieved a revenue of 774 million yuan in Q1-Q3 2024, a year-on-year increase of 29.84%, and a net profit attributable to shareholders of 65.56 million yuan, up 2.06% from the previous year. The net profit excluding non-recurring items increased by 27.25% year-on-year [2]. - The growth in revenue is primarily driven by the expansion of the sports nutrition and general nutrition product lines, supported by increased marketing efforts, which saw sales expenses rise by 48.84% to 128 million yuan [2]. - The company is well-positioned to benefit from the growing sports industry in China, with the number of fitness enthusiasts expected to exceed 460 million by 2027, creating a favorable environment for the demand for sports health products [3]. - Continuous investment in research and development has strengthened the company's competitive edge, with R&D expenses increasing to over 30 million yuan in 2023, reflecting a compound annual growth rate of 19.37% [3]. Financial Forecast and Valuation - The company is projected to achieve net profits of 104 million yuan, 123 million yuan, and 144 million yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.83 yuan, 0.99 yuan, and 1.16 yuan per share [4]. - The current price-to-earnings (P/E) ratios are estimated at 19, 16, and 14 times for the years 2024, 2025, and 2026, respectively, indicating a favorable valuation relative to expected earnings growth [4].

证券代码：833429 证券简称：康比特 公告编号：2024-061 已经就本次募集资金的存放签订了《募集资金三方监管协议》，募集资金已存储 于募集资金专户。 二、募集资金投资项目的具体情况 根据公司《招股说明书》，公司本次公开发行股票的募集资金将用于投资以 下项目： 其中，"品牌建设与推广项目"已结项，详见《关于注销部分募集资金专项账户的公告》 （公告编号：2024-041）、《2024 年半年度募集资金存放与实际使用情况的专项报告》（2024- 046）。 北京康比特体育科技股份有限公司 关于增加部分募投项目投资规模的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 北京康比特体育科技股份有限公司（以下简称"公司"）于2024年10月25日 召开第六届董事会第八次会议、第六届监事会第八次会议，审议通过了《关于增 加部分募投项目投资规模的议案》，同意"运动营养食品生产基地建设项目"增 加投资规模。保荐机构出具了无异议的核查意见，本事项尚需提交公司股东大会 审议批准。现将具体事项公告如下： 一、募集 ...